did attempt to arrive at an estimate using individual hospital data. They calculated that India was likely seeing 14 mucormycosis cases per 100,000 people, or an average of 171,504 cases per year.
If correct, this estimate makes India the mucormycosis capital of the world, with a prevalence that is 70 times the global average.
Scientists speculate that the large number of patients with uncontrolled diabetes in India, along with climatic conditions that favour high numbers of Mucorales spores in the air, contribute to these numbers.
But Chakrabarti cautions that modelled prevalence estimates can be very different from reality, because they involve too many assumptions.